Reports

Drug name	NICE TAs	Comments
Golimumab injection	TA233 - Golimumab for the treatment of ankylosing spondylitis TA220 - Golimumab for the treatment of psoriatic arthritis TA225 - Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs	Hospital use only
Guselkumab	TA711 - Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs
Hydrocortisone 0.5% cream	TA81 - Frequency of application of topical corticosteroids for atopic eczema	Mild potency
Hydrocortisone 0.5% ointment	TA81 - Frequency of application of topical corticosteroids for atopic eczema	Mild potency
Hydrocortisone 1% cream	TA81 - Frequency of application of topical corticosteroids for atopic eczema	Mild potency
Hydrocortisone 1% ointment	TA81 - Frequency of application of topical corticosteroids for atopic eczema	Mild potency
Ibrutinib	TA429 - Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation TA491 - Ibrutinib for treating Waldenstrom’s macroglobulinaemia TA502 - Ibrutinib for treating relapsed or refractory mantle cell lymphoma
Icosapent Ethyl	TA805 - Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides
Idelalisib (Zydelig)	TA359 - Idelalisib for treating chronic lymphocytic leukaemia
Imatinib (Glivec®)	TA70 - Guidance on the use of imatinib for chronic myeloid leukaemia (partially updated by TA241 and TA251) TA86 - Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours TA326 - Imatinib for the adjuvant treatment of gastrointestinal stromal tumours TA209 - Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours TA426 - Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia TA241 - Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance	Off-label use for melanoma with responsive c-KIT mutation

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports